Barinthus Biotherapeutics (BRNS) Competitors $1.10 -0.03 (-2.65%) Closing price 09/12/2025 03:50 PM EasternExtended Trading$1.10 0.00 (-0.36%) As of 09/12/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. TIL, MDWD, AARD, ENTA, TVGN, CGTX, BIOA, DERM, ACTU, and FTLFShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Instil Bio (TIL), MediWound (MDWD), Aardvark Therapeutics (AARD), Enanta Pharmaceuticals (ENTA), Tevogen Bio (TVGN), Cognition Therapeutics (CGTX), BioAge Labs (BIOA), Journey Medical (DERM), Actuate Therapeutics (ACTU), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors Instil Bio MediWound Aardvark Therapeutics Enanta Pharmaceuticals Tevogen Bio Cognition Therapeutics BioAge Labs Journey Medical Actuate Therapeutics FitLife Brands Barinthus Biotherapeutics (NASDAQ:BRNS) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Which has more risk & volatility, BRNS or TIL? Barinthus Biotherapeutics has a beta of -0.75, suggesting that its share price is 175% less volatile than the S&P 500. Comparatively, Instil Bio has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Do institutionals & insiders have more ownership in BRNS or TIL? 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 10.7% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 47.2% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, BRNS or TIL? Barinthus Biotherapeutics has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M2.99-$61.07M-$1.73-0.64Instil BioN/AN/A-$74.14M-$12.92-1.87 Does the media prefer BRNS or TIL? In the previous week, Instil Bio had 5 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 6 mentions for Instil Bio and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.91 beat Instil Bio's score of -0.52 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Barinthus Biotherapeutics Very Positive Instil Bio Negative Do analysts prefer BRNS or TIL? Barinthus Biotherapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 172.73%. Instil Bio has a consensus target price of $88.50, suggesting a potential upside of 267.22%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Barinthus Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Instil Bio 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is BRNS or TIL more profitable? Instil Bio's return on equity of -54.32% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -54.70% -44.75% Instil Bio N/A -54.32%-33.65% SummaryInstil Bio beats Barinthus Biotherapeutics on 8 of the 13 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.01M$3.19B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.6421.4375.3425.98Price / Sales2.99429.44514.54181.13Price / CashN/A46.6837.5660.44Price / Book0.349.6112.156.29Net Income-$61.07M-$53.29M$3.29B$271.07M7 Day Performance-11.29%0.13%0.74%3.87%1 Month Performance-10.57%5.61%4.82%4.88%1 Year Performance-14.06%10.49%60.58%26.12% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics2.9941 of 5 stars$1.10-2.7%$3.00+172.7%-14.1%$46.01M$14.97M-0.64107Positive NewsGap UpHigh Trading VolumeTILInstil Bio2.8538 of 5 stars$29.22+8.2%$119.00+307.3%-48.1%$182.27MN/A-2.26410Analyst ForecastInsider TradeMDWDMediWound1.6374 of 5 stars$16.60-0.6%$32.25+94.3%+1.3%$180.49M$20.22M-6.2980Gap UpAARDAardvark Therapeutics3.6904 of 5 stars$8.86+6.7%$32.60+267.9%N/A$180.08MN/A0.0018News CoverageHigh Trading VolumeENTAEnanta Pharmaceuticals4.1737 of 5 stars$9.00+7.1%$22.25+147.2%-32.1%$179.57M$67.64M-2.08160Positive NewsHigh Trading VolumeTVGNTevogen Bio3.9072 of 5 stars$0.89-2.2%$10.00+1,023.6%+75.8%$179MN/A0.003CGTXCognition Therapeutics2.8075 of 5 stars$2.43flat$2.83+16.6%+259.5%$178.66MN/A-3.6320Short Interest ↑BIOABioAge Labs0.1978 of 5 stars$4.65-5.7%N/AN/A$176.74MN/A0.00N/AHigh Trading VolumeDERMJourney Medical2.5449 of 5 stars$7.12-1.2%$12.17+70.9%+41.9%$175.77M$56.13M-18.7490ACTUActuate Therapeutics2.5143 of 5 stars$8.70+3.1%$20.33+133.7%-16.1%$175.09MN/A0.0010FTLFFitLife Brands4.3344 of 5 stars$18.05-3.1%$22.00+21.9%+5.0%$174.86M$64.47M21.4920Positive News Related Companies and Tools Related Companies TIL Competitors MDWD Competitors AARD Competitors ENTA Competitors TVGN Competitors CGTX Competitors BIOA Competitors DERM Competitors ACTU Competitors FTLF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BRNS Stock Alerts